Sign Up
Stories
Minerva Neurosciences Advances CNS Therapies
Share
ABVC BioPharma's Patent and Partnership
Addex Therapeutics Enters ADS Offering A...
Addex Therapeutics Meeting
Otsuka's Phase 3 Trial Results
Parkinson's Disease Epidemiology Forecas...
Therapeutics Advances Alzheimer’s Treatm...
Overview
API
Minerva Neurosciences discloses Q1 2024 financials, receives FDA response on roluperidone NDA, and advances CNS therapies.
Ask a question
How might the FDA's response impact Minerva Neurosciences' future drug development plans?
In what ways could the development of roluperidone and MIN-301 potentially revolutionize the treatment landscape for CNS disorders?
What challenges and opportunities could arise from the Phase 1b trial results on roluperidone co-administration?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage